Accessibility Menu
 
Bicycle Therapeutics Plc logo

Bicycle Therapeutics Plc

(NASDAQ) BCYC

Current Price$4.80
Market Cap$239.66M
Since IPO (2019)-60%
5 Year-85%
1 Year-47%
1 Month-2%

Bicycle Therapeutics Plc Financials at a Glance

Market Cap

$239.66M

Revenue (TTM)

$63.50M

Net Income (TTM)

$219.03M

EPS (TTM)

$-3.17

P/E Ratio

-1.51

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$4.80

Volume

400,434.393

Open

$4.68

Previous Close

$4.80

Daily Range

$4.62 - $4.91

52-Week Range

$4.24 - $9.36

BCYC: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bicycle Therapeutics Plc

Industry

Biotechnology

Employees

288

CEO

Kevin Lee, PhD, MBA

Headquarters

Cambridge, CB22 3AT, GB

BCYC Financials

Key Financial Metrics (TTM)

Gross Margin

-68%

Operating Margin

-4%

Net Income Margin

-3%

Return on Equity

-31%

Return on Capital

-40%

Return on Assets

-34%

Earnings Yield

-66.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$239.66M

Shares Outstanding

49.93M

Volume

400.43K

Avg. Volume

475.02K

Financials (TTM)

Gross Profit

$72.59M

Operating Income

$247.72M

EBITDA

$212.18M

Operating Cash Flow

$249.68M

Capital Expenditure

$2.36M

Free Cash Flow

$252.61M

Cash & ST Invst.

$628.11M

Total Debt

$17.52M

Bicycle Therapeutics Plc Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$887.00K

-91.1%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$239.66M

N/A

Market Cap/Employee

$785.78K

N/A

Employees

305

N/A

Net Income

$60.83M

-0.1%

EBITDA

$65.48M

+6.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$545.60M

-30.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$13.87M

+307.8%

Short Term Debt

$0.00

-100.0%

Return on Assets

-33.57%

N/A

Return on Invested Capital

-40.15%

N/A

Free Cash Flow

$66.64M

+23.7%

Operating Cash Flow

$65.92M

+24.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CMPXCompass Therapeutics, Inc.
$1.96+10.73%
FULCFulcrum Therapeutics, Inc.
$7.36+3.23%
NMRANeumora Therapeutics, Inc. Common Stock
$2.44-1.21%
FDMT4D Molecular Therapeutics, Inc.
$9.09+2.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.70+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$65.30+0.03%
NIONio
$5.91-0.08%

Questions About BCYC

What is the current price of Bicycle Therapeutics Plc?

Bicycle Therapeutics Plc is trading at $4.80 per share.

What is the 52-week range for Bicycle Therapeutics Plc?

Over the past 52 weeks, Bicycle Therapeutics Plc has traded between $4.24 and $9.36.

How much debt does Bicycle Therapeutics Plc have?

As of the most recent reporting period, Bicycle Therapeutics Plc reported total debt of $15.94M.

How much cash does Bicycle Therapeutics Plc have on hand?

Bicycle Therapeutics Plc reported $560.02M in cash and cash equivalents in its most recent financial results.

What is Bicycle Therapeutics Plc’s dividend yield?

Bicycle Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.